SEP 1 2 2005

PTO/SB/08A (10/01) (modified)
S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

O.S. Falent and Haderlark Onice, O.S. DEFARTMENT OF COMMERCE													
Substitute for form 1449A/PTO				THE STATE OF THE S		Application Number		09/546,573					
Substitute for form 1449A/PTO INFORMATION DISCLOSURE				DEMAT	Filing Date		April 10, 2000						
STATEMENT BY APPLICANT (use as many sheets as necessary)				,	First	Named Inventor	HOLTEN-ANDERSEN						
	•	use as man	y Silecis i	as riecessary	,	Art L	Init	1643					
						Exar	niner Name	S. L. Rawlings					
Sheet		1	of	1		Atto	ney Docket Number	59866.000002					
	U.S. PATENT DOCUMENTS												
		II			U.S. PA	TENI	DOCUMENTS		 				
*Examin		DOCL	MENT N	LIMBER			1		Pages, Column				
er	Cite				D. L. P		1	Where Relevan					
Initials	No.	Numb	er - Kind known)		Publication MM-DD-Y		Name of Patente Applicant of Cited De			iges or Relevan Jures Appear		ınt	
	1	US 20	04/15727	78 A1	08/12/2004		Astle, et al.						
Sis		US 20	104/01	5727841	8/12/2	004	Astle, et.	al.					
			<u>/</u>	· · ·									
		<u> </u>						_					
					FOREIGN	PATE	NT DOCUMENTS						
			EIGN PA OCUMEI					Pages, Columns, Lines,		TDAN	TRANSLA		
*Examin		Country Code:		er - Kind (if known)		Publication Date Name of Patentee or					TION		
er Initial	Cite No.	0000.	0000	(II KIIOWII)					Relevant			N	
					MM-DD-YYY		т тр		Figures Appear		YES	0	
5R	2	EP		71771	10/19/2000		Holten-Andersen, et al.						
SR	3	EP	138	81631	10/31/2002		Pan, <i>et al</i> .						
				THER DOC	JMENTS - NO	N-PA	TENT LITERATURE DOC	UMENTS					
											ANSLA	TIO	
*Examin	0'-	Include	name of t	he author (in	CAPITAL LET	TERS), title of the article (when	appropriat	e), title of the	N			
er teitiete	Cite	item	(book, m	agazine, jour	nal, serial, syr	nposiu	m, catalog, etc.), date, pad	re(s), volu	me-issue			N	
Initials	No.	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published YES						Ö					
										1			
							-				_		
EXAMIN	EXAMINER SIGNATURE / DATE CONSIDERED 3/24/06												
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

PTO/SB/08B (08/03) (modified)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO	SPONT & TR	ADEMA	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 3

Sheet

	Application Number	09/546,573			
	Filing Date	April 10, 2000 Mads HOLTEN-ANDERSEN, et al.			
	First Named Inventor				
	Art Unit	1643			
	Examiner Name	S. L. Rawlings			
	Attorney Docket Number	59866,000002			

U.S. PATENT DOCUMENTS Pages, Columns, Lines.							
*Examiner Initiats	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
SR	1.	US10/470,658	03-28-2005	Lasse L. HESSEL, et al.	-		
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-		1			
		US-					
		US-					
		US-					
		US-		·			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
EXAMINER SIGNATURE /				DATE CONSIDERED Z	122/06		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08B (08/03) (modified)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for form 1449/PTO Application Number 09/546,573 Filing Date April 10, 2000 INFORMATION DISCLOSURE Mads HOLTEN-ANDERSEN, et First Named Inventor STATEMENT BY APPLICANT (use as many sheets as necessary) Art Unit 1643 Examiner Name S. L. Rawlings Sheet 2 of 3 Attorney Docket Number 59866.000002 OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the TRANSLATION Cite *Examina item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published YES NO 2. Agency for Health Care Policy and Research, "Colorectal Cancer Screening: Summary", Evidence Report: Number 1. AHCPR Publ. No. 97-0302, pg. 1-4. SR П 3. Aznavoorian S. et al., "Molecular Aspects of Tumor Cell Invasion and Metastasis", Cancer, 15, 71(4), pg. 1368-1383, 1993. 4. Balk, S. P. et al., "Biology of Neoplasia, Biology of Prostate-Specific Antigen", Journal of Clinical Oncology, 21 (2), pg. 383-391, 2003. 5. Benson, A. B., et al., "ASCO Special Article - 2000 Update of American Society Colorectal Cancer Surveillance Guidelines", Journal of Clinical Oncology, 18(20), pg. 3586-3588, October 15, 2000. 6. Birkedal-Hansen, "Role of Matrix Metlloproteinases in Human Periodontal Diseases", J. Periodontal., pg. 474-484, May 1993. 7. Breimer, D. D., et al., "Saliva: A Fluid for Measuring Drug Concentrations", Pharmacy Internation, 1, pg. 9-11, 1980. 8. Khokha, R. et al., "AntisenseRNA-Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss 3T3 Cells", Science, 243, pg. 947-950, February 17, 1989. 9. Kleiner, et al., "Stability Analysis of Latent and Active 72-kDa Type IV Collagenase: The Role of Tissue Inhibitor of Metalloproteinases-2 (TIMP-2)", Biochemistry, 32, pg. 1583-1592, 1993. 10. Lovgren, J., et al., "Measurement of Prostate-Specific Antigen and Human Glandular Kallikrein 2 in Different Body Fluids", J. Andrology, 20, pg. 348-355, 1999. 11. Remacle, A. et al., "High Levels of TIMP-2 Correlate with Adverse Prognosis in Breast Cancer", Int. J. Cancer, 89, pp: 118-121, 2000. 12. Stetler-Stevenson WG et al., "Matrix Metalloproteinases and Tumor Invasion: From П Correlation and Causality to the Clinic", Semin. Cancer. Biol., 7, pp. 147-154, 1996. **EXAMINER SIGNATURE** DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08B (08/03) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ute for	form 1449/PTO	Application Number	09/546,573				
INI	5 0	RMATION DISCLOSURE	Filing Date	April 10, 2000	April 10, 2000			
	TAT	TEMENT BY APPLICANT	First Named Inventor	Made HOLTEN-ANDERSEN, et al.				
	(U	se as many sheets as necessary)	Art Unit	1643				
		<u> </u>	Examiner Name	S. L. Rawlings				
Sheet		3 of 3	Attorney Docket Number	59866.000002				
		OTHER DOCUMENTS - NON	I-PATENT LITERATURE	DOCUMENTS				
*Examiner Initials	Cite No.	item (book, magazine, journal, serial,	LETTERS), title of the article (when ap , symposium, catalog, etc.), date, page er, city and/or country where published	LETTERS), title of the article (when appropriate), title of the symposium, catalog, etc.), date, page(s), volume-issue r, city and/or country where published				
SR	13.		Prostate-Specific Antigen Levels in Saliva and the			×0		
	14.	Vignola et al., "Sputum Metalloproteir Correlates with Airflow Obstruction in A Care Med., 158, pp. 1945-1950, 1998.	Vignola et al., "Sputum Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio Correlates with Airflow Obstruction in Asthma and Chronic Bronchitis", Am. J. Respir. Crit. Care Med., 158, pp. 1945-1950, 1998.					
	15.	Vining, R. and McGinley, RA, "Hormor Science, 23, pp. 95-146, 1985.	Vining, R. and McGinley, RA, "Hormones in Saliva", Critical Reviews in Clinical Laboratory Science, 23, pp. 95-146, 1985.					
	16.		Welgus HG et al., "Human Skin Fibroblast Collagenase Interaction with Substrate and Inhibitor", Coll. Relat. Res., 5, pp. 167-179, 1985.					
	17.	Wolff, K. et al., Hay. A., "Methadone in S	Wolff, K. et al., Hay. A., "Methadone in Saliva", Clinical Chemistry, 37, pp. 1297-1298, 1991.					
	18.	Inhibitor of Metalloproteinase-1 in Voide	Garrett, C. Durkan et al., "Prognostic Significance of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-1 in Voided Urine Samples from Patients with Transitional Cell Carcinoma of the Bladder", Clin. Cancer Res., 7, pp. 3450-3456, Nov. 2001.					
	19.	Birkedal-Hansen, H. et al., "Matrix Me Med., 4(2), pp 197-250, 1993.	etalloproteinases: A Review	, Crit. Rev. Oral. Biol.				
+	20.	McCarthy K. et al., "High Levels of 7 Outcome in Patients with Breast Cance	McCarthy K. et al., "High Levels of Tissue Inhibitor of Metalloproteinase-1 Predict Poor Outcome in Patients with Breast Cancer", Int. J. Cancer, 84, pp. 44-48, 1999.					
EXAMI	NER!	SIGNATURE /	DATE CONSIDERED	3/24/06				
*EXAM citation	INER	: Initial if reference considered, whether or in conformance and not considered. Include	not citation is in conformance	with MPEP 609. Draw li	ine thro	ough		